In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.36 a new company low.

Within Major Pharmaceutical Preparations industry 400 other companies have achieved higher Quick Ratio than Ultragenyx Pharmaceutical Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1239 to 2933.

Explain Quick Ratio?
How much Cash & cash equivalents RARE�s has?
What are RARE�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RARE Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	61.29 %	13.04 %	6.69 %	-7.96 %	-20.25 %
Y / Y Cash & cash equivalent Change	-74.36 %	-16.47 %	11.47 %	-31.59 %	-36.17 %
Quick Ratio MRQ	0.36	1.63	2.24	1.62	2.24
RARE's Total Ranking	# 2933	# 1239	# 330	# 1161	# 838
Seq. Current Liabilities Change	38.74 %	-16.5 %	15.5 %	20.55 %	-2.77 %
Seq. Cash & cash equivalent Change	-69.73 %	-39.26 %	59.91 %	-12.78 %	-1.39 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 401
Healthcare Sector	# 764
Overall Market	# 2933

Quick Ratio Statistics
High	Average	Low
24.28	7.11	0.36
(Mar 31 2014)		(Jun 30 2026)

Financial Statements
Ultragenyx Pharmaceutical Inc 's Current Liabilities	$ 351 Millions	Visit RARE's Balance sheet
Ultragenyx Pharmaceutical Inc 's Cash & cash equivalent	$ 125 Millions	Visit RARE's Balance sheet
Source of RARE's Sales		Visit RARE's Sales by Geography

Cumulative Ultragenyx Pharmaceutical Inc 's Quick Ratio

RARE's Quick Ratio for the trailling 12 Months

RARE Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	15.73 %	-2.79 %	-7.42 %	-8.87 %	-4.03 %
Y / Y Cash & cash equivalent TTM Growth	-25.77 %	-19.44 %	-13.3 %	-15.05 %	0.84 %
Quick Ratio TTM	1.41	1.94	2.07	2.04	2.19
Total Ranking TTM	# 4016	# 2908	# 1467	# 3068	# 2661
Seq. Current Liabilities TTM Growth	12.88 %	2.9 %	1.92 %	-2.24 %	-5.18 %
Seq. Cash & cash equivalent TTM Growth	-18.08 %	-3.9 %	3.47 %	-8.87 %	-11.09 %

Quick ratio ranking by company, industry and sector >> Back to RARE Financial Strength Comparisons >> Go to Compare RARE Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q2 2026 to $351.00 millions, cumulative Quick Ratio decreased to 1.41 below the Ultragenyx Pharmaceutical Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 437 other companies have achieved higher Quick Ratio than Ultragenyx Pharmaceutical Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2908 to 4016.

Explain Quick Ratio?
How much Cash & cash equivalents RARE�s has?
What are RARE�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 438
Healthcare Sector	# 900
Within the Market	# 4016

trailing twelve months Quick Ratio Statistics
High	Average	Low
5.86	2.03	0.4
(Mar 31 2015)		(Sep 30 2023)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Akebia Therapeutics Inc	0.97	$ 155.548 Millions	$ 160.865 Millions
Syndax Pharmaceuticals Inc	0.95	$ 342.883 Millions	$ 360.284 Millions
Nurix Therapeutics Inc	0.94	$ 67.840 Millions	$ 72.020 Millions
Theriva Biologics inc	0.94	$ 11.337 Millions	$ 12.111 Millions
Geron Corporation	0.92	$ 64.781 Millions	$ 70.331 Millions
Zomedica Corp	0.84	$ 7.605 Millions	$ 9.002 Millions
Cocrystal Pharma Inc	0.83	$ 2.169 Millions	$ 2.616 Millions
Harrow Inc	0.82	$ 83.889 Millions	$ 102.171 Millions
Cue Biopharma Inc	0.82	$ 17.414 Millions	$ 21.218 Millions
Zoetis Inc	0.81	$ 1,676.000 Millions	$ 2,061.000 Millions
Organogenesis Holdings Inc	0.81	$ 46.097 Millions	$ 56.963 Millions
Bridgebio Pharma Inc	0.81	$ 720.160 Millions	$ 890.648 Millions
Nrx Pharmaceuticals Inc	0.79	$ 26.686 Millions	$ 33.874 Millions
Oncolytics Biotech Inc	0.79	$ 4.115 Millions	$ 5.225 Millions
Moleculin Biotech Inc	0.78	$ 7.262 Millions	$ 9.313 Millions
Seres Therapeutics Inc	0.78	$ 15.594 Millions	$ 20.031 Millions
Travere Therapeutics Inc	0.77	$ 117.735 Millions	$ 152.025 Millions
Arcus Biosciences Inc	0.77	$ 153.000 Millions	$ 198.000 Millions
Alkermes Plc	0.77	$ 511.529 Millions	$ 662.091 Millions
Integrated Biopharma Inc	0.77	$ 4.471 Millions	$ 5.802 Millions
Cyclerion Therapeutics Inc	0.75	$ 1.391 Millions	$ 1.843 Millions
Dar Bioscience Inc	0.75	$ 12.618 Millions	$ 16.923 Millions
Heron Therapeutics Inc	0.70	$ 64.643 Millions	$ 92.145 Millions
Amphastar Pharmaceuticals Inc	0.70	$ 331.903 Millions	$ 476.848 Millions
Axsome Therapeutics Inc	0.69	$ 319.850 Millions	$ 460.446 Millions
Zentalis Pharmaceuticals Inc	0.66	$ 24.783 Millions	$ 37.709 Millions
Pfizer Inc	0.64	$ 20,881.000 Millions	$ 32,646.000 Millions
Enanta Pharmaceuticals Inc	0.62	$ 33.419 Millions	$ 54.166 Millions
60 Degrees Pharmaceuticals Inc	0.61	$ 1.023 Millions	$ 1.685 Millions
Eton Pharmaceuticals Inc	0.59	$ 26.845 Millions	$ 45.124 Millions

Date modified: 2026-09-11T09:54:08+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.